Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

It won't because the problem with regenerative medicine is that if they actually work they will bankrupt the government and the health insurance industry.

Look at the $450k a pop immunotherapy that was just approved and was developed using tax payer money. Imagine when the industry matures and every therapy is looking for $500k a pop? Medicare bankrupt, health insurance premiums will go up.

ENDV's therapies are scalable like making iPhones, the more you make the less they cost. The non-invasive nature can also help make clinical trials shorter and less expensive.